423 related articles for article (PubMed ID: 19410471)
1. Positron emission tomography and [18F]BPA: a perspective application to assess tumour extraction of boron in BNCT.
Menichetti L; Cionini L; Sauerwein WA; Altieri S; Solin O; Minn H; Salvadori PA
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S351-4. PubMed ID: 19410471
[TBL] [Abstract][Full Text] [Related]
2. PET pharmacokinetic analysis to estimate boron concentration in tumor and brain as a guide to plan BNCT for malignant cerebral glioma.
Nariai T; Ishiwata K; Kimura Y; Inaji M; Momose T; Yamamoto T; Matsumura A; Ishii K; Ohno K
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S348-50. PubMed ID: 19375930
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part II.
Imahori Y; Ueda S; Ohmori Y; Sakae K; Kusuki T; Kobayashi T; Takagaki M; Ono K; Ido T; Fujii R
Clin Cancer Res; 1998 Aug; 4(8):1833-41. PubMed ID: 9717809
[TBL] [Abstract][Full Text] [Related]
4. 4-Borono-2-
Ishiwata K
Ann Nucl Med; 2019 Apr; 33(4):223-236. PubMed ID: 30820862
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the pharmacokinetics between L-BPA and L-FBPA using the same administration dose and protocol: a validation study for the theranostic approach using [
Watanabe T; Hattori Y; Ohta Y; Ishimura M; Nakagawa Y; Sanada Y; Tanaka H; Fukutani S; Masunaga SI; Hiraoka M; Ono K; Suzuki M; Kirihata M
BMC Cancer; 2016 Nov; 16(1):859. PubMed ID: 27821116
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of fluorine-18-BPA-fructose for boron neutron capture treatment planning.
Kabalka GW; Smith GT; Dyke JP; Reid WS; Longford CP; Roberts TG; Reddy NK; Buonocore E; Hübner KF
J Nucl Med; 1997 Nov; 38(11):1762-7. PubMed ID: 9374349
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography-based boron neutron capture therapy using boronophenylalanine for high-grade gliomas: part I.
Imahori Y; Ueda S; Ohmori Y; Sakae K; Kusuki T; Kobayashi T; Takagaki M; Ono K; Ido T; Fujii R
Clin Cancer Res; 1998 Aug; 4(8):1825-32. PubMed ID: 9717808
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the total distribution volume of
Romanov V; Isohashi K; Alobthani G; Beshr R; Horitsugi G; Kanai Y; Naka S; Watabe T; Shimosegawa E; Hatazawa J
Ann Nucl Med; 2020 Mar; 34(3):155-162. PubMed ID: 31808134
[TBL] [Abstract][Full Text] [Related]
9. Uptake of 4-borono-2-[18F]fluoro-L-phenylalanine in sporadic and neurofibromatosis 2-related schwannoma and meningioma studied with PET.
Havu-Aurén K; Kiiski J; Lehtiö K; Eskola O; Kulvik M; Vuorinen V; Oikonen V; Vähätalo J; Jääskeläinen J; Minn H
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):87-94. PubMed ID: 16896669
[TBL] [Abstract][Full Text] [Related]
10. Suitability of boron carriers for BNCT: accumulation of boron in malignant and normal liver cells after treatment with BPA, BSH and BA.
Chou FI; Chung HP; Liu HM; Chi CW; Lui WY
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S105-8. PubMed ID: 19375330
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of 4-borono-2-18F-fluoro-L-phenylalanine-fructose as a probe for boron neutron capture therapy in a glioma-bearing rat model.
Wang HE; Liao AH; Deng WP; Chang PF; Chen JC; Chen FD; Liu RS; Lee JS; Hwang JJ
J Nucl Med; 2004 Feb; 45(2):302-8. PubMed ID: 14960653
[TBL] [Abstract][Full Text] [Related]
12. Selective uptake of p-boronophenylalanine by osteosarcoma cells for boron neutron capture therapy.
Ferrari C; Zonta C; Cansolino L; Clerici AM; Gaspari A; Altieri S; Bortolussi S; Stella S; Bruschi P; Dionigi P; Zonta A
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S341-4. PubMed ID: 19394838
[TBL] [Abstract][Full Text] [Related]
13. Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study.
Bergenheim AT; Capala J; Roslin M; Henriksson R
J Neurooncol; 2005 Feb; 71(3):287-93. PubMed ID: 15735919
[TBL] [Abstract][Full Text] [Related]
14. Similar T/N ratio between
Lin YC; Chou FI; Yang BH; Chang CW; Chen YW; Hwang JJ
Ann Nucl Med; 2020 Jan; 34(1):58-64. PubMed ID: 31650410
[TBL] [Abstract][Full Text] [Related]
15. MicroPET-based pharmacokinetic analysis of the radiolabeled boron compound [18F]FBPA-F in rats with F98 glioma.
Chen JC; Chang SM; Hsu FY; Wang HE; Liu RS
Appl Radiat Isot; 2004 Nov; 61(5):887-91. PubMed ID: 15308163
[TBL] [Abstract][Full Text] [Related]
16. A unique in vivo assessment of 4-[10B]borono-L-phenylalanine in tumour tissues for boron neutron capture therapy of malignant melanomas using positron emission tomography and 4-borono-2-[18F]fluoro-L-phenylalanine.
Ishiwata K; Shiono M; Kubota K; Yoshino K; Hatazawa J; Ido T; Honda C; Ichihashi M; Mishima Y
Melanoma Res; 1992 Sep; 2(3):171-9. PubMed ID: 1450671
[TBL] [Abstract][Full Text] [Related]
17. Non-invasive estimation of
Yoshimoto M; Honda N; Kurihara H; Hiroi K; Nakamura S; Ito M; Shikano N; Itami J; Fujii H
Cancer Sci; 2018 May; 109(5):1617-1626. PubMed ID: 29498142
[TBL] [Abstract][Full Text] [Related]
18. Quantification of Boron Compound Concentration for BNCT Using Positron Emission Tomography.
Balcerzyk M; De-Miguel M; Guerrero C; Fernandez B
Cells; 2020 Sep; 9(9):. PubMed ID: 32932575
[No Abstract] [Full Text] [Related]
19. The use of positron emission tomography to develop boron neutron capture therapy treatment plans for metastatic malignant melanoma.
Kabalka GW; Nichols TL; Smith GT; Miller LF; Khan MK; Busse PM
J Neurooncol; 2003; 62(1-2):187-95. PubMed ID: 12749713
[TBL] [Abstract][Full Text] [Related]
20. Boron neutron capture therapy (BNCT) inhibits tumor development from precancerous tissue: an experimental study that supports a potential new application of BNCT.
Monti Hughes A; Heber EM; Pozzi E; Nigg DW; Calzetta O; Blaumann H; Longhino J; Nievas SI; Aromando RF; Itoiz ME; Trivillin VA; Schwint AE
Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S313-7. PubMed ID: 19376711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
